Comparable Company Analysis: Ford Motor Company (F), Allergan plc (AGN)

Mindy Sparks
December 7, 2017

The investor is now holding 13,079,782 shares thanks to an increase of 11,940,529 new shares in their portfolio.

Allergan plc (NYSE:AGN) has a current MF Rank of 12330.

Allergan announced that its board has approved a stock repurchase program on Monday, September 25th that authorizes the company to repurchase $2.00 billion in shares. Honeywell International Inc. now owns 168,130 shares of the company's stock worth $40,871,000 after buying an additional 20,100 shares during the period.

The return on assets (ROA) (aka return on total assets, return on average assets), is one of the most widely used profitability ratios because it is related to both profit margin and asset turnover, and shows the rate of return for both creditors and investors of the company. The short interest to Allergan Plc's float is 2.38%. Fairbanks Capital Management Inc. now owns 5,480 shares of the company's stock worth $1,332,000 after buying an additional 70 shares during the period. The correct version of this story can be read at https://www.dispatchtribunal.com/2017/12/06/brown-advisory-inc-boosts-stake-in-allergan-plc-agn.html. Allergan plc now has an average analyst recommendation of 2.00 according to analysts. Hedge funds and other institutional investors own 86.40% of the company's stock. (NYSE:AGN) on strength during trading hours on Tuesday after an insider sold shares in the company. (UA) worth $153.43 million at the end of the most recent reporting period. Grassi Inv Mngmt owns 0.36% invested in Allergan plc (NYSE:AGN) for 8,395 shares. The company had a trading volume of 2,944,580 shares. They presently have a $187.73 price objective on the stock. When following the volatility of a stock, investors may be challenged with trying to decipher the correct combination of risk-reward to help maximize returns. A low ratio specifies that the company is possibly undervalued, while a higher than average P/S may suggest overvaluation. Toth Advisory has invested 0.06% in Allergan plc (NYSE:AGN).

Average Revenue Estimate for the current quarter is $4.27 Billion, according to consensus forecast of 18 analysts. The business had revenue of $4.03 billion for the quarter, compared to analysts' expectations of $4.04 billion. During the same period in the prior year, the company earned $3.32 earnings per share. The ROIC 5 year average is 0.016760 and the ROIC Quality ratio is 0.972542. The company was maintained on Thursday, October 26 by Piper Jaffray. After a recent check, it is observed that the insiders for the firm now own 0.10% shares. Adding a sixth ratio, shareholder yield, we can view the Value Composite 2 score which is now sitting at 35. The ex-dividend date of this dividend is Tuesday, May 16th.


Several equities research analysts have weighed in on the company. UBS reissued an "outperform" rating and set a $275.00 price target on shares of Allergan in a report on Wednesday, August 9th. Royal Bank Of Canada reiterated a "buy" rating and set a $285.00 target price on shares of Allergan in a research note on Wednesday, September 6th. The rating was maintained by JP Morgan with "Neutral" on Monday, October 30.

Among analysts who offered their Analysis on Allergan plc (AGN)-9 analysts issued Buy for the stock, 7 analysts gave Outperform rating, 7 think it's a Hold, 0 issued Underperform, while 0 analyst gave a Sell rating. Cowen & Co has "Hold" rating and $3700 target. Mizuho maintained the shares of AGN in report on Tuesday, November 1 with "Buy" rating. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. These ratios are price to earnings, price to cash flow, EBITDA to EV, price to book value, and price to sales. The shares were sold at an average price of $220.45, for a total transaction of $416,430.05. The disclosure for this sale can be found here. Company insiders own 0.36% of the company's stock.

Allergan plc, a specialty pharmaceutical company, develops, makes, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Other reports by Iphone Fresh

Discuss This Article

FOLLOW OUR NEWSPAPER